Press Releases
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)09/30/2022
- Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy09/29/2022
- Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 202709/14/2022
News Features
Media Library
Press Contact
Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052